Skip to main content
Marvel Biosciences Corp. logo

Marvel Biosciences Corp. — Investor Relations & Filings

Ticker · MRVL ISIN · CA57384M1077 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 255 across all filing types
Latest filing 2020-10-16 Regulatory Filings
Country CA Canada
Listing TSXV MRVL

About Marvel Biosciences Corp.

https://marvelbiotechnology.com/

Marvel Biosciences Corp. is a pre-clinical stage biotechnology company specializing in the discovery and development of transformative treatments for complex neurological and neurodevelopmental disorders, including Autism Spectrum Disorder, Rett Syndrome, and Fragile X Syndrome. The company's core strategy involves chemical innovation to create synthetic derivatives of existing approved molecules. This drug redevelopment approach leverages established mechanisms to accelerate development and reduce risk. Its lead candidate, MB-204, is a patented synthetic derivative that has demonstrated preclinical efficacy across these target indications and is currently advancing toward first-in-human studies.

Recent filings

Filing Released Lang Actions
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a certification letter by the CFO of Alphanco Venture Corp. certifying the review and fair presentation of the annual filings (AIF, annual financial statements, and MD&A) for the financial year ended July 31, 2020. It is a Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate, which is a regulatory certification related to annual filings. The document does not contain actual financial statements or detailed financial data but is an attestation by an officer. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the actual annual report or financial report. The document length is under 5,000 characters and is a certification, not the report itself.
2020-10-16 English
Annual MD&A - English.pdf
Management Reports Classification · 100% confidence The document is titled 'FORM 51-102F1 MANAGEMENT DISCUSSION AND ANALYSIS For the Year Ended July 31, 2020' and contains detailed management discussion and analysis (MD&A) of the company's financial performance, business overview, liquidity, capital resources, and critical accounting estimates. It references audited financial statements and provides substantive financial data and analysis for the fiscal year ended July 31, 2020. The length of the document (15,000 characters) and the detailed financial and operational discussion confirm it is a full MD&A report rather than a brief announcement or certification. Therefore, the document fits the category of Management Reports (MDA).
2020-10-16 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).pdf
Fund Information / Factsheet Classification · 85% confidence The document is very short (771 characters) and contains tabular data with dates and numerical values, but no narrative or detailed financial statements. It appears to be a brief financial summary or factsheet rather than a full report. There is no indication of an annual or quarterly report, audit, or management discussion. The presence of dates and financial figures suggests a summary of key facts or financial data. Given the brevity and content, this fits best with a Fund Information / Factsheet (FS) classification, which is typically a brief summary of key company facts and financials.
2020-10-16 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings Classification · 95% confidence The document is a Management Certification related to Form 13 501F1 for Class 1 and Class 3B Reporting Issuers, submitted to the Alberta Securities Commission. It contains officer certification statements and market value calculations for securities, but no substantive financial statements or detailed financial analysis. The document length is 4266 characters, which is relatively short and primarily consists of certification and fee calculation information. It does not present a full financial report or detailed management discussion. Therefore, it fits the criteria for a Regulatory Filing (RNS) as it is a certification and regulatory submission rather than a full financial report or announcement of a report.
2020-10-16 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 100% confidence The document is titled 'INDEPENDENT AUDITOR’S REPORT' and contains detailed audited financial statements for Alphanco Venture Corp. for the year ended July 31, 2020 and the period from incorporation August 1, 2018 to July 31, 2019. It includes the auditor's opinion, basis for opinion, material uncertainty related to going concern, responsibilities of management and auditors, and detailed financial statements such as statements of financial position, loss and comprehensive loss, cash flows, changes in equity, and notes to the financial statements. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content matches the characteristics of an Audit Report / Information filing, as it is a standalone audit report with accounting principles and audit results, not a full Annual Report (10-K) which would include broader management discussion and other sections. Therefore, the correct classification is AR (Audit Report / Information). FY 2020
2020-10-16 English
Notice of the meeting and record date - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a notice regarding the upcoming Annual General & Special Meeting of Alphanco Venture Corp., including details such as meeting date, record date, and voting information. It does not contain the actual meeting materials, minutes, or financial reports. The document is short (1242 characters) and serves as an announcement of the meeting and record date rather than the meeting content itself. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a Regulatory Filing (RNS). However, since it is specifically about the meeting notice and record date, it aligns more closely with DVA, which covers official results and voting rights announcements related to shareholder meetings. Given the absence of voting results, it is borderline, but the focus on meeting and record date points to DVA rather than RNS. Confidence is high due to clear meeting-related content and no financial data or report attached.
2020-10-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.